Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
25.7M
-
Number of holders
-
55
-
Total shares
-
7.16M
-
Shares change
-
+259K
-
Total reported value, excl. options
-
$31.4M
-
Value change
-
+$1.22M
-
Put/Call ratio
-
0.11
-
Number of buys
-
32
-
Number of sells
-
-17
-
Price
-
$4.38
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q4 2023
58 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q4 2023.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.16M shares
of 25.7M outstanding shares and own 27.82% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.53M shares), VANGUARD GROUP INC (1.03M shares), Westside Investment Management, Inc. (563K shares), Acuitas Investments, LLC (492K shares), PARADIGM CAPITAL MANAGEMENT INC/NY (300K shares), BlackRock Inc. (284K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (253K shares), GEODE CAPITAL MANAGEMENT, LLC (227K shares), Parkman Healthcare Partners LLC (199K shares), and AMERIPRISE FINANCIAL INC (162K shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.